Krukenberg tumors (KT) are ovarian metastases originating from non-gynecological malignancies, typically associated with a poor prognosis. This study aimed to evaluate the demographic profile and outcomes of these patients based on our institutional experience.

We conducted a retrospective analysis of 21 patients diagnosed with KT between 2022 and 2025. Clinical characteristics, treatment modalities, and survival outcomes were assessed.

The mean age of the cohort was 42.5 years. Abdominal pain was the most frequent presenting symptom. Gastrointestinal primaries accounted for 71.42% of cases, predominantly arising from the colon and stomach. Bilateral ovarian involvement was observed in 16 out of 21 patients. The median overall survival was 9 months. At the time of analysis, 18 patients had succumbed to the disease. Subset analysis revealed improved survival among patients with a intestinal primary, unilateral ovarian metastasis, and those who completed more than six cycles of chemotherapy.

Due to metastatic nature of disease, KT have poor prognosis. Reducing tumor burden with chemotherapy appears to be a feasible option, although survival is still dismal. Patients with an intestinal primary site appear to have a more favourable outcome compared to other sites.